## Clinical Evaluation of a Commercial Hyperimmune Plasma Product in Dogs with Parvoviral Enteritis (Abstract ID02)

## **ACVIM 2018**

**Rachel Acciacca**<sup>1</sup>; Lauren Sullivan<sup>2</sup>; Tracy Webb<sup>2</sup>; Valerie Johnson<sup>2</sup>; Steven Dow<sup>2</sup>

<sup>1</sup>Colorado State University, Fort Collins, CO, USA; <sup>2</sup>Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA

This randomized, placebo-controlled clinical trial prospectively evaluated the safety and clinical efficacy of a single infusion of hyperimmune plasma (HIP) when administered to dogs with canine parvovirus (CPV). Client-owned CPV dogs were randomized to receive either placebo [n=16, 0.9% NaCl (10 mL/kg IV)] or the study drug [n=16, HIP (10 mL/kg IV)] within the first six hours of hospital admission. Supportive care was standardized for both groups throughout the duration of hospitalization.

Dogs within the HIP group demonstrated a lower shock index at the 12-hour mark (p=0.046), and this difference was still observable at the 24-hour mark (p=0.04). Blood lactate concentration was lower at the 24-hour mark in the HIP dogs when compared to the placebo dogs (p=0.049), although this was not statistically different at the 48-hour mark (p=0.10). There was no difference in duration of hospitalization between groups (p=0.35). Overall survival was 16/16 (100%) for the HIP group, compared to 14/15 (93.3%) for the placebo group (p=0.48). HIP was well tolerated with no adverse events noted during drug administration.

Results of this study indicate that hyperimmune plasma improves cardiovascular parameters during the first 24 hours of hospitalization. This study did not identify a difference in clinical severity improvement, duration of hospitalization, or mortality when comparing HIP and placebo dogs. Future studies evaluating HIP dose, and timing of HIP administration relative to disease onset, are needed to better determine the clinical benefit of this product.

## **SPEAKER INFORMATION**

(click the speaker's name to view other papers and abstracts submitted by this speaker)

Rachel Acciacca (/members/cms/project/defaultadv1.aspx? pld=20886&meta=generic&authorld=75811)

Colorado State University Fort Collins, CO, USA